Livagen 20mg

This guide helps laboratory buyers evaluate Livagen identity, published literature, analytical testing, and supplier records. Review the COA, peptide purity data, lot traceability, and RUO labeling separately from findings reported in experimental studies.

• Livagen is a short peptide commonly described in research databases as H-Lys-Glu-Asp-Ala-OH, with the sequence Lys-Glu-Asp-Ala and the molecular formula C18H31N5O9 [1].
• Published Livagen research includes chromatin, heterochromatin, ribosomal gene activity, and cultured lymphocyte model discussions, but those findings stay within literature interpretation [2] [3].
• Researchers evaluating a Livagen peptide listing should check RUO labeling, certificate of analysis availability, batch-specific documentation, and supplier documentation consistency.
• Peptide purity review should not rely on a single number alone; HPLC, LC-MS, chromatogram records, and mass data can support different parts of analytical review [18] [20].
• Literature on peptide bioregulators, Livagen and Epitalon, enzyme assays, and cellular models should not be translated into product-use claims [6].
• Catalog amounts, vial labels, and product listings are documentation fields, not recommendations, instructions, or study-design guidance.

Fast Answer: What Should Researchers Check Before They Buy Livagen for Research?

Researchers evaluating where to buy Livagen for research should review RUO labeling, compound identity, batch-specific COA, peptide purity data, LC-MS identity support, lot traceability, vial labeling, and storage documentation before procurement. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Analytical records should stay separate from product claims [18] [19].

Which Documentation Should Come Before Procurement?

Documentation should come before any procurement decision. A research buyer should first verify that the Livagen research material has a clear compound name, RUO status, lot number, certificate of analysis, purity method, identity method, and storage-record language.

Practical documentation checklist:

• Verify that Livagen is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are tied to a named analytical method.
• Check whether identity support includes mass data or another suitable record.
• Compare compound name, sequence, lot number, and label details across documents.
• Assess whether product-page language avoids product claims.
• Document storage and handling conditions in a laboratory record.

Why Does RUO Labeling Matter for Laboratory Research?

RUO labeling identifies the intended research context. FDA guidance for RUO-labeled in vitro diagnostic products distinguishes research-only labeling from diagnostic positioning [27] , and federal labeling language distinguishes research-only materials from diagnostic procedures [28] . These IVD-specific sources do not establish approval of the listed peptide.

Livagen Research-Use-Only Evaluation

Evaluate whether the Livagen material is described clearly, tested transparently, and labeled consistently.

What Does Research Use Only Mean for Livagen?

Livagen is supplied for laboratory research only. Review compound identity, COA fields, purity results, LC-MS identity evidence, and lot records before selection.

Research use does not mean that published findings become claims about the material being sold. This distinction is especially important with Livagen because the literature includes cell-model and chromatin-focused work that needs careful interpretation [2] [3].

Where Pure Lab Peptides Fits in Documentation Review

Compare the RUO label, listed identity, certificate of analysis, and analytical records supplied for the material.

Look for traceable peptide identity, purity results, and lot-specific supplier documentation.

What Is Livagen in Peptide Bioregulator Literature?

Livagen is a short peptide discussed in peptide bioregulator literature. PubChem lists the compound as H-Lys-Glu-Asp-Ala-OH, with the sequence Lys-Glu-Asp-Ala and formula C18H31N5O9 [1].

Relevant literature includes short peptide bioregulators, chromatin structure, cultured lymphocyte models, hepatocyte cultures, and enzyme assays. These studies do not establish effects of the listed material.

Livagen Peptide Identity and Research Classification

Livagen peptide identity begins with the sequence record. Lys-Glu-Asp-Ala indicates a tetrapeptide made from lysine, glutamic acid, aspartic acid, and alanine residues [1].

In research classification, Livagen is often grouped with short peptide bioregulators. Reviews on ultrashort peptides describe small peptide sequences as a distinct research area involving transport, gene-expression discussion, and model-specific peptide regulation [11].

What Does Short Peptide Bioregulator Research Examine?

Khavinson-associated literature discusses ultrashort peptides in gene-expression and protein-synthesis models [11] [12] . Interpret the findings within their specific research systems.

Why Does Tetrapeptide Sequence Documentation Matter?

Tetrapeptide sequence documentation matters because identity review starts with the compound record. Sequence, molecular formula, and molecular weight should align across the product page, COA, label, and supplier documentation.

Mass spectrometry can support identity review for synthetic peptides, while HPLC contributes separation and purity information [23] [24]. When those records disagree, the documentation needs further review.

Compound Identity: Peptide Sequence, Formula, and Catalog Listing

For Livagen, distinguish the peptide identity from the catalog amount or vial size. Compare sequence and molecular information across the supplier records.

A catalog listing may show an amount such as 20mg.

How Does Lys-Glu-Asp-Ala Support Identity Review?

Lys-Glu-Asp-Ala supports identity review because it gives researchers a sequence field to compare across the COA, label, and database record. PubChem’s Livagen entry lists the compound under H-Lys-Glu-Asp-Ala-OH and identifies the molecular formula as C18H31N5O9 [1].

Sequence alignment alone is not a complete analytical review. It should be paired with batch-specific testing records when available.

Why Should Molecular Weight Match Documentation?

Molecular weight is a consistency check. If a product page, COA, and identity-testing report list different molecular identity fields, the buyer should treat that as a documentation issue.

Analytical method guidance emphasizes that identification, impurity, and assay procedures require suitable validation characteristics for their intended analytical purpose [18]. For peptide materials, identity review is stronger when mass data and sequence expectations align [24].

How Vial Labeling Supports Research Material Tracking

A vial label supports research material tracking when the compound name, lot number, catalog amount, and RUO statement match the supplier documentation. The label should not be treated as a substitute for a COA.

For laboratory buyers, the practical question is simple: does the vial label match the product-page record and the batch-specific documentation?

How Published Literature Frames Livagen Research

Published literature frames Livagen as a subject in peptide bioregulator research. Key papers discuss chromatin activation, heterochromatin patterns, cultured lymphocyte models, enzyme-assay work, and organotypic culture models [2] [4] [6].

Which Khavinson and Lezhava References Need Review?

The Khavinson and Lezhava literature should be reviewed as model-specific research. A 2002 PubMed-indexed paper reported Livagen-associated changes in ribosomal gene activity and heterochromatin parameters in cultured lymphocyte material [2].

A later short-peptide chromatin paper discussed several peptides, including Livagen, in relation to ribosome-gene activation and heterochromatin changes [3] . Its findings apply to the materials and models studied.

How Do Cultured Lymphocyte Models Support Literature Context?

Cultured lymphocyte models support literature context because they let researchers examine cellular and chromatin-level endpoints in a controlled model. Livagen appears in published work focused on chromatin activation in cultured lymphocyte material [2].

A cell-model finding applies to its experimental system and does not establish an effect of the listed material.

Why Literature Findings Are Not Product Claims

A study observation, model condition, and experimental material do not establish the intended use or effect of a catalog product. Evaluate study results and supplier documentation separately.

Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.

Chromatin Context for Livagen Peptide Research

Chromatin is the DNA-protein packaging system that affects access to genetic information. Nucleosomes are a basic unit of chromatin organization, and chromatin compaction can influence gene regulation [17].

Published Livagen studies discuss chromatin activation, heterochromatin, euchromatin, and ribosomal gene activity in defined models [2] [3] .

How Does Chromatin Structure Appear in Mechanistic Literature?

Chromatin structure appears in mechanistic literature as a way to discuss DNA accessibility and gene regulation. NCBI Bookshelf material describes chromatin modification as a core mechanism for controlling gene expression [16].

General chromatin reviews distinguish between open and compact chromatin states and explain how chromatin-associated complexes can influence accessibility [13] [14]. Livagen-related chromatin papers should be read within that broader biology context.

What Do Pericentromeric and Telomeric Heterochromatin Add?

Pericentromeric and telomeric heterochromatin add regional detail to chromatin interpretation. A Lezhava and Jokhadze paper examined pericentromeric and telomeric heterochromatin in cultured lymphocyte material and discussed Livagen in that experimental context [4].

This provides context for interpreting the study, not evidence of an effect of the listed material.

Why Do Nucleolar and Gene-Expression Endpoints Require Model Context?

The nucleolus is associated with ribosomal RNA gene transcription and ribosome assembly [15] . Interpret measurements related to these processes within the conditions of each experiment.

Livagen literature has discussed ribosomal gene activity and chromatin activation in cultured lymphocyte models [2] . These are study endpoints, not established effects of the catalog material.

Cellular and Enzyme Assay Context in Published Models

Livagen also appears in cellular and enzyme-assay literature. Evaluate the experimental material, assay, and endpoint in each study.

How Does Lymphocyte Research Connect to Peptide Bioregulators?

Lymphocyte research connects to peptide bioregulators through published studies that examine chromatin structure and gene-expression-associated endpoints in cultured lymphocyte material. Livagen appears in that literature alongside other short peptide bioregulators [2] [5].

Those studies inform literature interpretation; they do not establish a practical application for this catalog material.

Where Do Enkephalin-Degrading Enzyme Assays Fit?

Enkephalin-degrading enzyme assays fit as biochemical literature context. Kost, Sokolov, Gabaeva, Zolotarev, Malinin, and Khavinson examined Livagen and Epitalon in an enzyme-assay study involving enkephalin-degrading enzymes in human serum [6].

Other Livagen literature includes digestive enzyme activity, organotypic liver culture, tissue-culture, and hepatocyte protein-synthesis models [7] [8] [9] [10] . The findings apply to the specific experimental materials and conditions studied.

What Does Pathway Relevance Establish?

Chromatin, heterochromatin, gene expression, and enzyme assays are research topics. Their appearance in a study does not establish the same observations for a supplied catalog lot.

Certificate of Analysis Review for Livagen

A certificate of analysis is one of the most important documents on a research peptide product page. It should connect testing information to the specific batch being evaluated.

The COA should not be treated as a marketing badge. It is a technical document that needs cross-checking against the product page, label, and lot record.

What Should a Certificate of Analysis Show?

A Livagen certificate of analysis should show the compound name, lot number, testing date, purity result, analytical method, and identity-support method when available. Analytical method guidance emphasizes that procedures should be suitable for their intended analytical purpose [18] [19].

Documentation-focused verification workflow:

1. Verify the compound name, lot number, and vial label match across records.
2. Review the batch-specific COA.
3. Check whether the purity testing method is listed.
4. Confirm whether identity support includes LC-MS, mass spectrometry, or another suitable analytical record.
5. Review chromatogram or mass data when available.
6. Check the COA date and laboratory source.
7. Record storage and handling documentation in the laboratory file.

How Batch-Specific Documentation Supports Research Procurement

Batch-specific documentation supports procurement because analytical data should map to the material being evaluated. A generic COA or unmatched lot record creates uncertainty.

Reference-standard work in synthetic peptide quality shows why lot homogeneity, identity, content, stability, and purity are distinct documentation concepts [22]. Research buyers should look for batch-level clarity, not broad claims.

Why Do COA Dates and Lot Numbers Matter?

COA dates and lot numbers matter because they anchor testing records in time and batch identity. Analytical procedure lifecycle guidance treats documentation and change control as part of maintaining reliable analytical procedures [29].

Peptide Purity and Analytical Testing Considerations

Peptide purity and identity are related, but not identical. A purity value may describe chromatographic peak area under a stated method, while identity support asks whether the material matches the expected peptide.

HPLC purity results and LC-MS identity evidence answer different questions and are useful to review together.

How Does HPLC Support Purity Review?

HPLC supports purity review by separating components under defined chromatographic conditions. USP <621> covers chromatographic procedures, and peptide HPLC literature explains major HPLC modes used for peptide analysis and purification [20] [21].

For Livagen, an HPLC purity result is stronger when it is batch-specific and paired with method details. It should not be read as a complete identity record on its own.

How Does LC-MS Support Peptide Identity Confirmation?

LC-MS supports peptide identity confirmation by pairing chromatographic separation with mass data. Synthetic peptide characterization literature describes LC-MS and targeted MS approaches as useful for identity and impurity profiling [23].

Mass spectrometry is widely used for peptide and protein analysis because it can provide molecular-mass and fragmentation information [25]. For short peptides, specialized LC-MS methods can help distinguish closely related sequences [26].

What Can Chromatogram and Mass Data Clarify?

A chromatogram can clarify retention behavior and peak profile under a named method. Mass data can clarify whether the observed mass aligns with the expected peptide identity.

Together, these records support a better documentation review than either one alone. FDA analytical guidance also treats specificity, accuracy, precision, and related validation characteristics as central to method evaluation [18] [19].

Laboratory Documentation for Supplier Evaluation

Supplier evaluation should compare documentation systems, not promotional language. The strongest research supplier records are consistent across product page, vial label, COA, lot number, purity data, and identity testing.

This makes Livagen procurement review a technical process. It is less about claims and more about document alignment.

What Should Research Buyers Compare Across Suppliers?

Research buyers should compare COA access, lot traceability, identity fields, testing methods, label consistency, and RUO statements. They should also check whether a supplier avoids converting published literature into product claims.

A source-quality filter helps:

• Peer-reviewed literature for scientific context.
• Official databases for identity fields.
• Analytical method documents for testing concepts.
• COA and lot records for supplier-specific review.
• RUO labeling for intended-use limitations.

How Label Consistency Supports Procurement Review

Label consistency supports procurement review because the label is the physical anchor for the laboratory record. If the vial label says one thing and the COA says another, the discrepancy should be resolved before the material is logged.

The label should match the compound name, lot number, catalog amount, and RUO statement.

Why Third-Party Testing Documentation Adds Context

Third-party testing documentation can add context when it identifies the testing laboratory, method, date, batch, and reported values. It is most useful when the document is traceable and method-specific.

A testing claim is only as useful as the records behind it.

Storage and Handling Documentation for Lyophilized Peptides

Lyophilized peptide documentation should describe storage conditions, packaging state, and handling records at a high level. Freeze drying is widely used in pharmaceutical and biopharmaceutical processing because it can support dry-state preservation of moisture-sensitive materials [30].

What Handling Notes Belong on RUO Materials?

RUO materials should include handling notes that support laboratory recordkeeping, such as storage conditions, lot number, container status, and documentation matching.

They should not include personal-use instructions or consumer-oriented guidance.

Why Storage Records Support Laboratory Traceability

Storage records support laboratory traceability by showing how a material was logged and maintained after receipt. For lyophilized peptides, the key documentation point is whether supplier storage language is recorded and followed within the laboratory’s own controlled system.

Storage records support reproducibility, accountability, and traceability of laboratory materials.

Common Misunderstandings Before Researchers Buy Livagen for Research

The most common problem is turning literature terms into product claims.

Another misunderstanding is treating an analytical result as if it answered every documentation question. Purity, identity, lot traceability, and label consistency each need separate review.

Key Evidence Distinctions for Livagen Evaluation

Keep these distinctions in mind when reviewing the material:

• Published literature does not equal product-use guidance.
• Cell-model findings should not become product claims.
• A purity value does not prove complete identity by itself.
• A COA should be batch-specific.
• RUO labeling does not support personal-use positioning.
• Catalog amounts are listing fields, not study instructions.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Review the product-page documentation, COA details, analytical testing records, and RUO labeling before evaluating Livagen for laboratory research.

FAQs

What does research use only mean for Livagen?

Livagen is supplied solely for laboratory research, not human or veterinary use. Review compound identity, COA records, analytical testing, lot traceability, and supplier documentation. Published findings do not establish effects or suitability of the listed material.

What should researchers consider before they buy Livagen for research?

Researchers should consider documentation first before they buy Livagen for research. The key review points are RUO labeling, batch-specific COA availability, peptide identity support, purity data, lot-number consistency, and storage documentation. Research buyers should also confirm that product-page language stays focused on research purposes and avoids unsupported claims.

How should published literature about Livagen be interpreted?

Published literature about Livagen should be interpreted as model-specific research context. Studies discussing chromatin activation in lymphocytes, telomeric heterochromatin in cultured lymphocytes, or regulation of gene expression can inform literature review, but they should not be converted into claims about a research material [2]. The safest reading separates study findings from product documentation.

What is Livagen in bioregulatory peptide research?

Livagen is discussed as a bioregulatory peptide in research literature and is associated with the amino acid sequence Lys-Glu-Asp-Ala [1] . Compare this identity with the supplier records. Interpret epigenetic, cell-nucleus, and protein-biosynthesis findings within their cited experimental models.

Why does a COA matter for Livagen research materials?

A COA matters because it helps connect Livagen supplier documentation to batch-level analytical review. Researchers can compare the COA against the product label, lot number, purity method, and identity-support method. For research peptides and other research compounds, the COA is part of documentation review, not a substitute for full laboratory evaluation.

What role does bioregulator peptide research play in Livagen review?

Bioregulator peptide research provides background for interpreting Livagen studies. Evaluate the specific peptide, model, and measured endpoint in work on cell signaling, chromosome organization, ribosomal DNA, euchromatin, or proteases. These topics do not establish effects of the supplied material.

---

REFERENCES

1. National Center for Biotechnology Information. PubChem compound record for H-Lys-Glu-Asp-Ala-OH. PubChem. CID 87919683.
2. Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu. Chromatin activation study of Livagen in cultured lymphocyte material. Bulletin of Experimental Biology and Medicine. 2002. DOI: 10.1023/A:1021924702103. PMID: 12533768.
3. Khavinson VKh, Lezhava TA, Malinin VV. Short peptide chromatin study in lymphocyte material. Bulletin of Experimental Biology and Medicine. 2004. DOI: 10.1023/B:BEBM.0000024393.40560.05.
4. Lezhava T, Jokhadze T. Pericentromeric and telomeric heterochromatin study in cultured lymphocyte material. Annals of the New York Academy of Sciences. 2007. DOI: 10.1196/annals.1395.043. PMID: 17460203.
5. Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Peptide bioregulator chromatin reactivation study. Georgian Medical News. 2006. PMID: 16705247.
6. Kost NV, Sokolov OYu, Gabaeva MV, Zolotarev YuA, Malinin VV, Khavinson VKh. Livagen and Epitalon serum enzyme-assay study. Biology Bulletin. 2003. DOI: 10.1023/A:1024809822681.
7. Timofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV. Digestive enzyme activity study of Livagen in research models. Advances in Gerontology. 2005. PMID: 16075683.
8. Riadnova IIu, Kozina LS, Morozov VG, Khavinson VK. Organotypic liver culture study of Livagen. Advances in Gerontology. 2002. PMID: 12577697.
9. Khavinson VKh, Malinin VV, Chalisova NI, Grigor’ev EI. Tissue-culture study of peptides including Livagen. Advances in Gerontology. 2002. PMID: 12096446.
10. Brodskii VIa, Khavinson VKh, Zolotarev VA, Nechaeva NV, Malinin VV, Novikova TE, Gvazava IG, Fateeva VI. Hepatocyte protein-synthesis culture study involving Livagen. Izvestiia Akademii Nauk. Seriia Biologicheskaia. 2001. PMID: 15926314.
11. Khavinson V, Linkova N, Diatlova A, et al. Transport of biologically active ultrashort peptides using POT and LAT transporters. International Journal of Molecular Sciences. 2022.
12. Khavinson VKh, Solovev AYu. Epigenetic aspects of peptide-mediated regulation in aging research. Advances in Gerontology. 2012.
13. Allshire RC, Madhani HD. Ten principles of heterochromatin formation and function. Nature Reviews Molecular Cell Biology. 2017.
14. Morrison O, Thakur J. Molecular complexes at euchromatin, heterochromatin, and centromeric chromatin. International Journal of Molecular Sciences. 2021.
15. National Human Genome Research Institute. Nucleolus definition. Genome.gov Genetics Glossary.
16. NCBI Bookshelf. Chromatin mechanisms regulating gene expression. National Center for Biotechnology Information.
17. Sha K, Boyer LA. Basic unit of chromatin organization. StemBook, NCBI Bookshelf. 2009.
18. International Council for Harmonisation / FDA. Q2(R2) Validation of Analytical Procedures. FDA. 2022.
19. U.S. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics. FDA Guidance for Industry. 2015.
20. United States Pharmacopeia. USP General Chapter <621> Chromatography. USP. 2021.
21. Mant CT, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007.
22. McCarthy D, et al. Reference standards for synthetic peptide quality documentation. AAPS Journal. 2023.
23. Lian Z, et al. LC-MS workflow for synthetic peptide characterization. Journal of the American Society for Mass Spectrometry. 2021. DOI: 10.1021/jasms.0c00479.
24. Prabhala BK, et al. Mass spectrometry characterization of synthetic peptides. Methods in Molecular Biology. 2015. PMID: 26424265.
25. Zhang G, Annan RS, Carr SA, Neubert TA. Overview of peptide and protein analysis by mass spectrometry. Current protocols in protein science. 2010. PMID: 21104985.
26. Hollebrands B, et al. LC-MS identification of short homologous peptides. Analytical and Bioanalytical Chemistry. 2023.
27. U.S. Food and Drug Administration. Distribution of products labeled for research use only or investigational use only. FDA Guidance. 2013; content current 2018.
28. Electronic Code of Federal Regulations. 21 CFR Part 809: In vitro diagnostic products. eCFR.
29. United States Pharmacopeia. USP General Chapter <1220> Analytical Procedure Life Cycle. USP.
30. Pardeshi SR, et al. Freeze-drying process development and quality attributes review. Future Journal of Pharmaceutical Sciences. 2023.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.